利妥昔单抗联合CHOP方案对弥漫大B细胞淋巴瘤患者血清PDGF-BB、LDH及三系血细胞的影响  

Effects of rituximab combined with CHOP regimen on serum PDGF-BB,LDH and three-line blood cells in patients with diffuse large B-cell lymphoma

作　　者：王超 黄蓉 WANG Chao;HUANG Rong(Ankang Hospital of Traditional Chinese Medicine,Ankang 725000,China)

机构地区：[1]安康市中医医院,陕西安康725000

出　　处：《临床医学研究与实践》2023年第27期25-28,共4页Clinical Research and Practice

摘　　要：目的 观察利妥昔单抗联合CHOP方案对弥漫大B细胞淋巴瘤(DLBCL)患者血清血小板衍生生长因子-BB(PDGF-BB)、乳酸脱氢酶(LDH)及三系血细胞的影响。方法 选择2018年1月至2021年1月我院收治的80例DLBCL患者为研究对象,根据治疗方案不同将其分为CHOP组(40例,CHOP方案)和R-CHOP组(40例,利妥昔单抗联合CHOP方案)。比较两组的治疗效果。结果 R-CHOP组的疾病控制率(DCR)高于CHOP组,国际预后指数(IPI)评分低于CHOP组(P<0.05)。治疗后,R-CHOP组的PDGF-BB、LDH、血管内皮生长因子(VEGF)、β_(2)微球蛋白(β_(2)-MG)水平低于CHOP组(P<0.05)。治疗后,两组的白细胞计数(WBC)、血红蛋白(Hb)、中性粒细胞与淋巴细胞比值(NLR)、血小板计数(PLT)均低于治疗前,但R-CHOP组高于CHOP组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 利妥昔单抗联合CHOP方案治疗DLBCL患者可提高肿瘤控制效果,降低血清标志物水平,且对三系血细胞影响较小,安全性较好,值得应用。Objective To observe the effects of rituximab combined with CHOP regimen on serum platelet-derived growth factor-BB(PDGF-BB),lactate dehydrogenase(LDH)and three-line blood cells in patients with diffuse large B-cell lymphoma(DLBCL).Methods A total of 80 patients with DLBCL admitted in our hospital from January 2018 to January 2021 were selected as the research objects.According to different treatment regimens,the patients were divided into CHOP group(40 cases,CHOP regimen)and R-CHOP group(40 cases,rituximab combined with CHOP regimen).The therapeutic effects of the two groups were compared.Results The disease control rate(DCR)of the R-CHOP group was higher than that of the CHOP group,and the International Prognostic Index(IPI)score was lower than that of the CHOP group(P<0.05).After treatment,the levels of PDGF-BB,LDH,vascular endothelial growth factor(VEGF)andβ_(2)-microglobulin(β_(2)-MG)in the R-CHOP group were lower than those in the CHOP group(P<0.05).After treatment,the white blood cell count(WBC),hemoglobin(Hb),neutrophil lymphocyte ratio(NLR)and platelet count(PLT)in the two groups were lower than those before treatment,but those in the R-CHOP group were higher than the CHOP group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Rituximab combined with CHOP regimen in the treatment of DLBCL patients can improve the effect of tumor control,reduce the levels of serum markers,and has little effect on three-line blood cells,with good safety,which is worthy of application.

关 键 词：弥漫大B细胞淋巴瘤 利妥昔单抗 CHOP方案 

分 类 号：R733.1[医药卫生—肿瘤]